Skip to main content
Q32 Bio Inc. logo

Q32 Bio Inc. — Investor Relations & Filings

Ticker · QTTB ISIN · US7469641051 LEI · 549300RWKPJEFTM3K452 US Professional, scientific and technical activities
Filings indexed 506 across all filing types
Latest filing 2026-05-05 Quarterly Report
Country US United States of America
Listing US QTTB

About Q32 Bio Inc.

https://www.q32bio.com/

Q32 Bio Inc. is a clinical-stage biotechnology company developing therapies to restore healthy immune balance in patients with autoimmune and inflammatory diseases. The company's therapeutic approach targets powerful regulators of both the innate and adaptive immune systems. Its most advanced product candidate, bempikibart (ADX-914), is a fully human anti-interleukin-7 receptor alpha (IL-7Rα) antagonist monoclonal antibody. Bempikibart is designed to re-regulate adaptive immune function by blocking signaling from both interleukin-7 (IL-7) and thymic stromal lymphopoietin (TSLP). The candidate is currently being evaluated in a Phase 2 program for the treatment of alopecia areata.

Recent filings

Filing Released Lang Actions
10-Q - Q32 Bio Inc. (0001661998) (Filer)
Quarterly Report
2026-05-05 English
8-K - Q32 Bio Inc. (0001661998) (Filer)
Regulatory Filings
2026-05-05 English
ARS - Q32 Bio Inc. (0001661998) (Filer)
Annual Report
2026-04-30 English
DEF 14A - Q32 Bio Inc. (0001661998) (Filer)
Proxy Solicitation & Information Statement
2026-04-30 English
424B5 - Q32 Bio Inc. (0001661998) (Filer)
Prospectus
2026-04-24 English
4 - Q32 Bio Inc. (0001661998) (Issuer)
Director's Dealing
2026-03-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.